Nedosiran
Modify Date: 2025-08-25 15:44:19
Nedosiran structure
|
Common Name | Nedosiran | ||
|---|---|---|---|---|
| CAS Number | 2266591-83-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NedosiranNedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate[1][2][3]. |
| Name | Nedosiran |
|---|
| Description | Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Nedosiran (DCR-PHXC) is an investigational ribonucleic acid interference (RNAi) therapy[2]. Nedosiran is a synthetic, double-stranded RNA oligonucleotide (i.e., small interfering RNA [siRNA]) designed to target the mRNA encoding LDHA[2]. |
| In Vivo | Nedosiran is a RNAi therapy for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase[3]. Nedosiran specially inhibits hepatic expression of lactate dehydrogenase (LDHA)[3]. Nedosiran is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran is administered by monthly subcutaneous injection. Nedosiran decreases plasma oxalate in animal models[3]. |
| References |
| No Any Chemical & Physical Properties |